Lithuania vs Western Pacific (WHO region): Previously treated cases tested for RR-/MDR-TB
Lithuania
100.0%
in 2024
Western Pacific (WHO region)
86.0%
in 2024
Lithuania rank
1st
Western Pacific (WHO region) rank
3rd
Previously treated cases tested for RR-/MDR-TB over time
- Lithuania
- Western Pacific (WHO region)
How they compare
Lithuania currently reports 100.0% against 86.0% in Western Pacific (WHO region), a difference of 14.0%.
That makes Lithuania's figure about 1.2 times Western Pacific (WHO region)'s.
Across all 20 years both countries report, Lithuania has been ahead every year.
Lithuania ranks 1st and Western Pacific (WHO region) ranks 3rd of 180 countries.
Lithuania has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Lithuania | Western Pacific (WHO region) | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 98.4% | 1.0% | 97.4% | Lithuania |
| 2010s | 100.0% | 54.9% | 45.1% | Lithuania |
| 2020s | 100.0% | 89.2% | 10.8% | Lithuania |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Lithuania or Western Pacific (WHO region)?
- Lithuania, at 100.0% against 86.0% in Western Pacific (WHO region) as of 2024.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Lithuania and Western Pacific (WHO region)?
- 14.0%, with Lithuania ahead.
- How many years of comparable data are there for Lithuania and Western Pacific (WHO region)?
- 20 years are reported by both, from 2005 to 2024.
- How do Lithuania and Western Pacific (WHO region) rank globally for previously treated cases tested for rr-/mdr-tb?
- Lithuania ranks 1st and Western Pacific (WHO region) ranks 3rd of 180 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.